Z hypnotics in the management of narcolepsy: a case series
Abstract
Study objectives: Here we report our experience treating patients with narcolepsy using benzodiazepine receptor agonists, zolpidem, or eszopiclone taken at bedtime for both excessive daytime sleepiness and cataplexy.
Methods: We reviewed the medical records of 53 patients diagnosed with narcolepsy, between 2002 and 2023. Twenty-three patients, 8 with narcolepsy type 1 (NT1), 13 with narcolepsy type 2 (NT2), and 2 with secondary narcolepsy, were treated with benzodiazepine receptor agonists (20 zolpidem and 3 eszopiclone).
Results: Seven out of 8 (88%) with narcolepsy type 1, 9 out of 13 (69%) with NT1, and 2 out of 2 (100%) with secondary narcolepsy, treated with benzodiazepine receptor agonists, had good to excellent self-reported response in their symptoms of excessive daytime sleepiness and/or cataplexy; 5 patients, 1 of whom with NT1, had marginal or no response. Three of the responding patients remained on zolpidem in monotherapy (ie, no stimulants).
Conclusions: The benzodiazepine receptor agonists drugs may be effective to manage several of the cardinal symptoms of narcolepsy, regardless of the narcolepsy type. Placebo controlled trials are needed to confirm our observations.
Citation: Aboukasm A, Reffi AN, Drake CL. Z hypnotics in the management of narcolepsy: a case series. J Clin Sleep Med. 2025;21(5):753-756.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 53 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.